WuXi Biologics (Cayman) Inc. (BKK:WUXI06)

Market Cap	544.50B
Revenue (ttm)	90.92B
Net Income (ttm)	19.02B
Shares Out	n/a
EPS (ttm)	4.48
PE Ratio	28.62
Forward PE	22.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,051
Average Volume	404,635
Open	3.380
Previous Close	3.400
Day's Range	3.300 - 3.380
52-Week Range	3.300 - 4.020
Beta	n/a
RSI	29.61
Earnings Date	Nov 19, 2025

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact...

• Industry: Commercial Physical and Biological Research
• Founded: 2014
• Employees: 12,575
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: WUXI06

Financial Performance

In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.

Financial numbers in CNY